About Trastuzumab (OGIVRI)
            
            Class: | Monoclonal antibody (HER2/neu receptor antagonist)  
Use: | Treatment of HER2-positive breast cancer (metastatic and adjuvant settings) and gastric cancer  
Adult dose: | 8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks or 2 mg/kg weekly, depending on the treatment regimen  
Pediatric dose: | Safety and efficacy not established in pediatric patients; use is not recommended  
Side effects: | Common side effects include infusion-related reactions, nausea, diarrhea, fatigue, headach
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (HER2/neu receptor antagonist)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of HER2-positive breast cancer (metastatic and adjuvant settings) and gastric cancer
                 
                
                
                    
                        Storage Requirements
                    
                    Store refrigerated at 2°C to 8°C (36°F to 46°F); do not freeze; protect from light
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: MYLAN PHARMACEUTICAL PRIVATE LIMITED, India
                    
                    
                    Package Size
                    50ml Vial
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 5444.50
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks or 2 mg/kg weekly, depending on the treatment regimen
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy not established in pediatric patients; use is not recommended
                    
                 
                
                
                    
                        Side Effects
                    
                    Common side effects include infusion-related reactions, nausea, diarrhea, fatigue, headache, and rash
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Known hypersensitivity to trastuzumab or any component of the formulation; history of severe infusion reactions
         
        
        
            
                Important Warnings
            
            Risk of cardiotoxicity, particularly in patients with pre-existing heart conditions; monitor cardiac function; potential for pulmonary toxicity; may cause fetal harm if administered during pregnancy
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.